Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.
<h4>Aim</h4>The role of insulin glargine as a risk factor for cancer is controversial in human studies. The aim of this meta-analysis was to evaluate the relationship between insulin glargine and cancer incidence.<h4>Methods</h4>All observational studies and randomized contro...
Guardado en:
Autores principales: | Xulei Tang, Lin Yang, Zhiyu He, Jingfang Liu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/13714cf8c35a4c73948ef31ba6116386 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan TJE, et al.
Publicado: (2021) -
On the safety of insulin Glargine
por: Ivan Ivanovich Dedov, et al.
Publicado: (2009) -
Lantus (Insulin Glargin): new insulin on Russian market
por: Editorial team Diabetes Mellitus
Publicado: (2003) -
Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
por: Liu D, et al.
Publicado: (2021) -
Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
por: Vadim Valer'evich Klimontov, et al.
Publicado: (2014)